Bio Pharma Primo Impex is a cGMP-certified supplier of high-purity pharmaceutical intermediates with complete DMF dossiers, CEP filings, and multi-market regulatory compliance. Your trusted manufacturing partner for APIs and key starting materials globally.
29+
Intermediates
6+
DMF Filings
cGMP
Certified
βοΈ Quality at Every Step
Our intermediates and APIs are synthesised with the utmost precision and undergo rigorous quality checks β purity levels that exceed international benchmarks across IP, BP, USP, and EP pharmacopoeias.
π Regulatory Excellence
Manufacturing processes adhere to ICH Q7 GMP guidelines, certified by CDSCO, WHO-GMP, PMDA, and ISO. DMF dossiers available for USA (USFDA), Europe (CEP), Korea (KDMF), Japan (JDMF), and Brazil (ANVISA).
π Reliable Global Supply
Consistent, uninterrupted supply to pharmaceutical manufacturers across 80+ countries. Custom synthesis and long-term contract manufacturing available as per client specifications and process requirements.
π
β€οΈ
Cardiovascular
8 Intermediates
Product / API
Key Intermediates & CAS Numbers
DMF Status
Filing / Action
Azilsartan Medoxomil Potassium Salt
ARB Anti-Hypertensive
2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid [147403-03-0], Azilsartan Base
2-[(Diphenylmethyl)sulfinyl]acetamide intermediate β full specification on request
Not Filed
ποΈ
Oncology
1 Intermediate
Product / API
Key Intermediates & CAS Numbers
DMF Status
Filing / Action
Darolutamide Intermediates
Non-Steroidal Androgen Receptor Antagonist (ARi) β Prostate Cancer
4-Bromo-2-Chlorobenzonitrile β key building block for darolutamide synthesis
Not Filed
π¬
No intermediates found
Try adjusting your search or clearing the category filter.
β οΈ
Patent Notice: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. Bio Pharma Primo Impex supplies intermediates strictly for use in jurisdictions where no valid patent protection exists or where applicable compulsory licensing provisions apply.